Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus PULMOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus PULMOLITE.
MACROTEC vs PULMOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical